keyword
MENU ▼
Read by QxMD icon Read
search

Chemoradiation

keyword
https://www.readbyqxmd.com/read/29141164/lomustine-and-bevacizumab-in-progressive-glioblastoma
#1
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C Bromberg, Michael Platten, Martin Klein, Martin J van den Bent
BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS: We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients)...
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29140105/durvalumab-in-non-small-cell-lung-cancer-patients-current-developments
#2
Laura Mezquita, David Planchard
Immune checkpoint inhibitors (ICIs) are a key component of treating advanced cancer patients, principally antibodies against CTLA-4 and PD-1 or PD-L1. Durvalumab (MEDI4736) is a selective, high-affinity, human IgG1 monoclonal antibody that blocks PD-L1, which binds to PD-1 and CD80, but not to PD-L2. Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the ≥25% PD-L1+ population. Durvalumab is under evaluation in early, locally advanced and advanced disease as monotherapy and combined with ICIs, targeted therapies, chemotherapy and radiotherapy...
November 15, 2017: Future Oncology
https://www.readbyqxmd.com/read/29139215/treatment-utilization-and-outcomes-in-elderly-patients-with-locally-advanced-esophageal-carcinoma-a-review-of-the-national-cancer-database
#3
Gregory Vlacich, Pamela P Samson, Stephanie M Perkins, Michael C Roach, Parag J Parikh, Jeffrey D Bradley, A Craig Lockhart, Varun Puri, Bryan F Meyers, Benjamin Kozower, Cliff G Robinson
For elderly patients with locally advanced esophageal cancer, therapeutic approaches and outcomes in a modern cohort are not well characterized. Patients ≥70 years old with clinical stage II and III esophageal cancer diagnosed between 1998 and 2012 were identified from the National Cancer Database and stratified based on treatment type. Variables associated with treatment utilization were evaluated using logistic regression and survival evaluated using Cox proportional hazards analysis. Propensity matching (1:1) was performed to help account for selection bias...
November 15, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29138560/biodistribution-of-gold-nanoparticles-in-bbn-induced-muscle-invasive-bladder-cancer-in-mice
#4
Henry M Smilowitz, Lauren J Tarmu, Mary Melinda Sanders, John A Taylor, Dharamainder Choudhary, Crystal Xue, Nathaniel A Dyment, Dan Sasso, Xiaomeng Deng, James F Hainfeld
Bladder-sparing options are being developed for muscle-invasive bladder cancer in place of radical cystectomy, including the combination of chemotherapy and radiation therapy. We reasoned that improving the radiotherapy component of chemoradiation could improve the control of locally advanced disease. Previously, we showed that gold nanoparticles (AuNPs) are potent enhancers of radiation therapy. We hypothesized that if AuNPs were to preferentially localize to bladder tumors, they may be used to enhance the radiation component of muscle-invasive bladder tumor therapy...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29137264/preoperative-chemoradiotherapy-for-rectal-cancer-the-sensitizer-role-of-the-association-between-mir-375-and-c-myc
#5
Raquel Conde-Muiño, Carlos Cano, Victoria Sánchez-Martín, Antonio Herrera, Ana Comino, Pedro P Medina, Pablo Palma, Marta Cuadros
Administration of chemoradiation before tumor resection has revolutionized the management of locally advanced rectal cancer, but many patients have proven resistant to this preoperative therapy. Our group recently reported a negative correlation between c-Myc gene expression and this resistance. In the present study, integrated analysis of miRNA and mRNA expression profiles was conducted in 45 pre-treatment rectal tumors in order to analyze the expressions of miRNAs and c-Myc and their relationship with clinicopathological factors and patient survival...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136962/impact-of-neoadjuvant-chemoradiation-on-lymph-node-status-in-esophageal-cancer-post-hoc-analysis-of-a-randomized-controlled-trial
#6
Koen Talsma, Bas Wijnhoven, Jan van Lanschot, Mark van Berge Henegouwen
No abstract text is available yet for this article.
December 2017: Annals of Surgery
https://www.readbyqxmd.com/read/29136212/neoadjuvant-and-adjuvant-therapy-for-stage-iii-non-small-cell-lung-cancer
#7
Shun-Ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada
The treatments for advanced non-small cell lung cancer (NSCLC) should control both local and microscopic systemic disease, because the 5-year survival of patients with Stage III NSCLC who underwent surgical resection alone has been dismal. One way to improve surgical outcome is the administration of chemotherapy before or after the surgical procedure. During the last two decades, many clinical studies have focused on developing optimal adjuvant or neoadjuvant chemotherapy regimens that can be combined with surgical treatment and/or radiotherapy...
November 9, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29135607/targeting-the-perivascular-niche-in-brain-tumors
#8
Giorgio Seano
PURPOSE OF REVIEW: Brain tumors are composed of primary tumors of the central nervous system, such us glioblastoma (GBM), and secondary metastatic tumors, such as melanoma, non-Hodgkin lymphoma as well as lung and breast cancers. Brain tumors are highly deadly, and unfortunately not many improvements have been achieved to improve the survival of patients with brain tumors. Chemoradiation resistance is one of the most clinically relevant challenges faced in patients with brain tumors. The perivascular niche is one of the most relevant microenvironment hubs in brain tumors...
November 14, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29135111/curative-intent-for-unresectable-advanced-squamous-cell-esophageal-cancer-overall-survival-after-chemoradiation
#9
Tatjana Arsenijevic, Marina Nikitovic, Vesna Plesinac-Karapandzic, Suzana Stojanovic-Rundic, Dusica Gavrilovic, Marjan Micev, Predrag Pesko
PURPOSE: To analyse the overall survival (OS) of patients with locally advanced, unresectable esophageal cancer treated with chemoradiation (CRT) with or without surgery. METHODS: CRT was administered to 63 patients with locally advanced (T3-4, N0-1), initially unresectable squamous cell esophageal cancer. After the assessment of tumor response to treatment, medically fit patients converted to operable stage were subjected to surgery. Regular follow-up was performed every 3 months during first 2 years, and then every 6 months...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29134385/robotic-assisted-multivisceral-resection-for-rectal-cancer-short-term-outcomes-at-a-single-center
#10
H Hino, T Yamaguchi, Y Kinugasa, A Shiomi, H Kagawa, Y Yamakawa, M Numata, A Furutani, Y Yamaoka, S Manabe, T Suzuki, S Kato
BACKGROUND: The safety and feasibility of robotic-assisted multivisceral resection for locally advanced rectal cancer remain unclear. The aim of this study was to assess the short-term outcomes of this procedure at our institution. METHODS: From December 2011 to December 2016, patients who underwent robotic-assisted multivisceral resection for rectal cancer were investigated. Patient demographics, treatment characteristics, perioperative outcomes, and pathological results were evaluated retrospectively...
November 13, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/29134378/organ-preservation-in-rectal-cancer-after-chemoradiation-should-we-extend-the-observation-period-in-patients-with-a-clinical-near-complete-response
#11
Britt J P Hupkens, Monique Maas, Milou H Martens, Marit E van der Sande, Doenja M J Lambregts, Stéphanie O Breukink, Jarno Melenhorst, Janneke B Houwers, Christiaan Hoff, Meindert N Sosef, Jeroen W A Leijtens, Maaike Berbee, Regina G H Beets-Tan, Geerard L Beets
BACKGROUND: To assess whether extending the observation period in patients with a near clinical complete response (near cCR) after chemoradiation (CRT) leads to an impaired oncological outcome. METHODS: Patients who had a clinical complete response (cCR) 8-10 weeks after CRT restaging with magnetic resonance imaging and endoscopy were offered a watch-and-wait strategy (W&W1), while patients with a near cCR were offered to undergo local excision or a second restaging 6-12 weeks later...
November 13, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29132485/prognostic-role-of-acellular-mucin-pools-in-patients-with-rectal-cancer-after-pathological-complete-response-to-preoperative-chemoradiation-systematic-review-and-meta-analysis
#12
Abu Bakar Hafeez Bhatti, Sidra Zaheer, Kashif Shafique
The prognostic implication of acellular mucin pools (AMP) in rectal cancer is controversial. There is no Level-I evidence regarding their prognostic impact. This systematic review was performed to determine the impact of AMPon survival in patients with rectal cancer, who demonstrate pathological complete response (PCR) to preoperative chemoradiation (CRT). Asystematic literature review was performed by searching MEDLINE and EMBASE database. For overall survival, the overall random effect model favored mucin negative tumors (HR=2, 95% CI=0...
November 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29127435/intensified-preoperative-chemoradiation-by-adding-oxaliplatin-in-locally-advanced-primary-operable-ct3nxm0-rectal-cancer-impact-on-long-term-outcome-results-of-the-phase%C3%A2-ii-tako-05-abcsg-r%C3%A2-02-trial
#13
P Kogler, A F DeVries, W Eisterer, J Thaler, L Sölkner, D Öfner
PURPOSE: The major goals of preoperative treatment for locally advanced rectal cancers (LARCs) are improvement of local tumor control, tumor downsizing, and downstaging. Modifications with respect to standardized chemoradiation protocol, e. g., integrating oxaliplatin, are realized with the aim of improving primary tumor response and patient outcome. PATIENTS AND METHODS: In this phase II multicenter study, patients with LARC of the mid- or lower rectum, cT3cNxcM0 as staged by MRI, were included and treated preoperatively with a combination of capecitabine and oxaliplatin following a standardized protocol during radiation...
November 10, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29126492/oral-cancer-genetics-and-the-role-of-precision-medicine
#14
REVIEW
Chia-Cheng Li, Zhen Shen, Roxanne Bavarian, Fan Yang, Aditi Bhattacharya
Oral squamous cell carcinoma (OSCC) is one of the leading cancers in the world. OSCC patients are managed with surgery and/or chemoradiation. Prognoses and survival rates are dismal, however, and have not improved for more than 20 years. Recently, the concept of precision medicine was introduced, and the introduction of targeted therapeutics demonstrated promising outcomes. This article reviews the current understanding of initiation, progression, and metastasis of OSCC from both genetic and epigenetic perspectives...
January 2018: Dental Clinics of North America
https://www.readbyqxmd.com/read/29126203/a-randomized-phase-ii-study-of-everolimus-in-combination-with-chemoradiation-in-newly-diagnosed-glioblastoma-results-of-nrg-oncology-rtog-0913
#15
Prakash Chinnaiyan, Minhee Won, Patrick Y Wen, Amyn M Rojiani, Maria Werner-Wasik, Helen A Shih, Lynn S Ashby, Hsiang-Hsuan Michael Yu, Volker W Stieber, Shawn C Malone, John B Fiveash, Nimish A Mohile, Manmeet S Ahluwalia, Merideth M Wendland, Philip J Stella, Andrew Y Kee, Minesh P Mehta
Background: This Phase II study was designed to determine the efficacy of the mTOR inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma. Methods: Patients were randomized to radiation therapy with concurrent and adjuvant temozolomide with or without daily everolimus (10 mg). The primary endpoint was progression-free survival (PFS) and the secondary endpoints were overall survival (OS) and treatment-related toxicities...
November 6, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29124039/surgical-management-of-stage-iiia-non-small-cell-lung-cancer
#16
REVIEW
Paul E Van Schil, Lawek Berzenji, Suresh K Yogeswaran, Jeroen M Hendriks, Patrick Lauwers
According to the eighth edition of the tumor-node-metastasis classification, stage III non-small cell lung cancer is subdivided into stages IIIA, IIIB, and IIIC. They represent a heterogeneous group of bronchogenic carcinomas with locoregional involvement by extension of the primary tumor and/or ipsilateral or contralateral lymph node involvement. Surgical indications have not been definitely established but, in general, long-term survival is only obtained in those patients in whom a complete resection is obtained...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29122306/carmustine-wafer-implantation-for-high-grade-gliomas-evidence-based-safety-efficacy-and-practical-recommendations-from-the-neuro-oncology-club-of-the-french-society-of-neurosurgery
#17
REVIEW
A Roux, F Caire, J Guyotat, P Menei, P Metellus, J Pallud
There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation). Compelling clinical data also support the safety of carmustine wafer implantation (grade A recommendation) in these patients and suggest that observed adverse events can be avoided in experienced neurosurgeon hands...
November 6, 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/29121621/a-review-of-squamous-cell-vulvar-cancers-in-waikato-region-new-zealand
#18
Prashanth Hari Dass, Marion Jj Kuper-Hommel
BACKGROUND: Squamous cell vulvar cancers (SCVC) are rare. Although management guidelines have recently been published, New Zealand studies presenting "real world" outcomes are limited. METHODS: Retrospective single-centre review of SCVC diagnosed between 1 January 2000 and 31 August 2015. Clinical characteristics and outcomes were reviewed. RESULTS: Among 47 cases reviewed, 38 were ethnically European and 9 Māori. Cases identified as Stage 1 (16), Stage 2 (5), Stage 3 (17), Stage 4 (9)...
November 10, 2017: New Zealand Medical Journal
https://www.readbyqxmd.com/read/29119649/prospective-multimodal-imaging-assessment-of-locally-advanced-cervical-cancer-patients-administered-by-chemoradiation-followed-by-radical-surgery-the-price-prospective-imaging-of-cervical-cancer-and-neoadjuvant-treatment-study-2-the-role-of-ultrasound-after
#19
Antonia Carla Testa, Francesca Moro, Tina Pasciuto, Maria Cristina Moruzzi, Alessia Di Legge, Gilda Fuoco, Rosa Autorino, Angela Collarino, Benedetta Gui, Gian Franco Zannoni, Antonietta Gambacorta, Maura Miccò, Vittoria Rufini, Giovanni Scambia, Gabriella Ferrandina
OBJECTIVE: To determine the diagnostic performance of two-dimensional ultrasound parameters, three-dimensional power Doppler and intravenous contrast enhanced indices in detecting residual disease in locally advanced cervical cancer patients triaged to neoadjuvant treatment followed by radical surgery. METHODS: Between October 2010 and June 2014, 108 women with histologically documented cervical cancer and FIGO stage IB2-IVA were screened and 88 of them were included in the final analysis...
November 8, 2017: Ultrasound in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29118088/ido-immune-status-after-chemoradiation-may-predict-survival-in-lung-cancer-patients
#20
Weili Wang, Lei Huang, Jian-Yue Jin, Shruti Jolly, Yong Zang, Huanmei Wu, Li Yan, Wenhu Pi, Lang Li, Andrew L Mellor, Feng-Ming Spring Kong
Host immunity influences the impact of radiotherapy (RT) in cancer but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non-small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during and after RT administration and then correlated to overall survival (OS), progression-free survival and disease progression rate in patients...
November 8, 2017: Cancer Research
keyword
keyword
18226
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"